

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104  
Estimated average burden  
hours per response: 0.5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>REESE DAVID M</u>  (Last) (First) (Middle) <u>ONE AMGEN CENTER DRIVE</u>  (Street) <u>THOUSAND OAKS</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>07/26/2018</u>	3. Issuer Name and Ticker or Trading Symbol <u>AMGEN INC [ AMGN ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP, Research and Development</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person			

## Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>17,732<sup>(1)(2)</sup></u>	<u>D</u>	

## Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Nqso (Right to Buy)</u>	<u>04/26/2012<sup>(3)</sup></u>	<u>04/26/2020</u>	<u>Common Stock</u>	<u>1,480</u>	<u>58.43</u>	<u>D</u>
<u>Nqso (Right to Buy)</u>	<u>04/25/2013<sup>(4)</sup></u>	<u>04/25/2021</u>	<u>Common Stock</u>	<u>2,300</u>	<u>54.69</u>	<u>D</u>
<u>Nqso (Right to Buy)</u>	<u>05/03/2018<sup>(5)</sup></u>	<u>05/03/2026</u>	<u>Common Stock</u>	<u>8,711</u>	<u>156.35</u>	<u>D</u>
<u>Nqso (Right to Buy)</u>	<u>05/01/2019<sup>(6)</sup></u>	<u>05/01/2027</u>	<u>Common Stock</u>	<u>8,714</u>	<u>162.6</u>	<u>D</u>
<u>Nqso (Right to Buy)</u>	<u>04/27/2020<sup>(7)</sup></u>	<u>04/27/2028</u>	<u>Common Stock</u>	<u>7,807</u>	<u>177.46</u>	<u>D</u>

## Explanation of Responses:

- These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 313 RSUs which vest fully in one installment on 1/30/2019; 686 RSUs which vest in installments of 338 and 348 on 5/3/2019 and 5/3/2020, respectively; 4,920 RSUs which vest in installments of 1,623, 1,624 and 1,673 on 5/1/2019, 5/1/2020 and 5/1/2021, respectively; 984 RSUs which vest in installments of 324, 325 and 335 on 5/1/2019, 5/1/2020 and 5/1/2021, respectively; and 1,014 RSUs which vest in installments of 334, 335 and 345 on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.
- These shares include 282 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- These options were fully exercisable on 4/26/2014.
- These options were fully exercisable on 4/25/2015.
- 2,874 of these options have vested and the remainder are exercisable in two installments of 2,875 and 2,962 on 5/3/2019 and 5/3/2020, respectively.
- These stock options are exercisable in three annual installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively.
- These stock options are exercisable in three annual installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.

/s/ David M. Reese

08/02/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Power of Attorney

Know all men by these presents, that the undersigned hereby constitutes and appoints each of Dennis Yai, Richard T. Benson, Andrea A. Robinson, signing singly, the undersigned's true and lawful attorney-in-fact to execute for and on behalf of the undersigned Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, as may be required as a result of the undersigned's position as an officer and/or director of Amgen Inc. (the "Company").

The undersigned hereby grants to each such attorney-in-fact full power and authority to execute such Forms 3, 4 and 5 as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 27th day of July, 2018.

/s/ David M. Reese  
Name: David M. Reese